Locally Advanced Pancreatic Adenocarcinoma Clinical Trials

18 recruiting

Locally Advanced Pancreatic Adenocarcinoma Trials at a Glance

18 actively recruiting trials for locally advanced pancreatic adenocarcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Detroit, Sacramento, and Irvine. Lead sponsors running locally advanced pancreatic adenocarcinoma studies include Azienda Ospedaliera di Padova, Baptist Health South Florida, and Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA).

Browse locally advanced pancreatic adenocarcinoma trials by phase

Treatments under study

About Locally Advanced Pancreatic Adenocarcinoma Clinical Trials

Looking for clinical trials for Locally Advanced Pancreatic Adenocarcinoma? There are currently 18 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Locally Advanced Pancreatic Adenocarcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Locally Advanced Pancreatic Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1Phase 2

A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.

Locally Advanced Pancreatic AdenocarcinomaLocally Advanced Pancreas CancerLocally Advanced Pancreatic Ductal Adenocarcinoma
Xerient Pharma36 enrolled4 locationsNCT07157033
Recruiting
Early Phase 1

First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer

Metastatic Pancreatic CancerLocally Advanced Pancreatic Adenocarcinoma
University of California, Davis30 enrolled1 locationNCT04665947
Recruiting
Phase 2

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinoma
Medical University of South Carolina52 enrolled1 locationNCT07076212
Recruiting
Phase 2

A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment

Locally Advanced Pancreatic Adenocarcinoma
University Health Network, Toronto43 enrolled2 locationsNCT06453486
Recruiting
Phase 1Phase 2

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8Locally Advanced Pancreatic Adenocarcinoma
National Cancer Institute (NCI)92 enrolled44 locationsNCT04172532
Recruiting
Phase 1

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma+1 more
PanTher Therapeutics26 enrolled6 locationsNCT06673017
Recruiting
Phase 2

Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma
EXACT Therapeutics AS25 enrolled10 locationsNCT06850623
Recruiting
Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma+2 more
SWOG Cancer Research Network94 enrolled274 locationsNCT06998940
Recruiting
Phase 2

Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Pancreas AdenocarcinomaLocally Advanced Pancreatic AdenocarcinomaBorderline Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences64 enrolled1 locationNCT05825066
Recruiting
Phase 3

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Metastatic Pancreatic CancerVenous ThromboembolismLocally Advanced Pancreatic Adenocarcinoma
Quercis Pharma AG480 enrolled3 locationsNCT06861088
Recruiting
Phase 2

Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+3 more
Mayo Clinic25 enrolled1 locationNCT06381154
Recruiting
Not Applicable

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

Pancreas CancerLocally AdvancedLocally Advanced Pancreatic Adenocarcinoma
Baptist Health South Florida48 enrolled1 locationNCT05679674
Recruiting
Phase 1Phase 2

Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma

Locally Advanced Pancreatic Adenocarcinoma
EIR Biotherapies s.r.l.9 enrolled1 locationNCT06861452
Recruiting
Phase 2

Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma
Institut du Cancer de Montpellier - Val d'Aurelle103 enrolled9 locationsNCT04570943
Recruiting

Surgery for Locally Unresectable Pancreatic Cancer

Locally Advanced Pancreatic Adenocarcinoma
Azienda Ospedaliera di Padova150 enrolled1 locationNCT07241663
Recruiting
Phase 3

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

SurgeryPancreas CancerNeoadjuvant Chemotherapy+3 more
Sahlgrenska University Hospital432 enrolled1 locationNCT06714604
Recruiting

Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer

SurgeryQuality of LifePancreas Cancer+6 more
Umeå University300 enrolled1 locationNCT05356039
Recruiting

PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer

Pancreatic CancerChemotherapy EffectLocally Advanced Pancreatic Adenocarcinoma+1 more
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)223 enrolled1 locationNCT05524090